Q1 2025 Laboratory Corp of America Holdings Earnings Call
Okay.
Speaker Change: Good day and thank you for standing by welcome to the Q1 'twenty 'twenty five Labcorp Holdings earnings Conference call. At this time, all participants are in a listen only mode. After the speaker's presentation. There will be a question and answer session to ask a question.
Speaker Change: During the session you will need to press star one one on your telephone you will then hear an automated message advising your hand, just raced to withdraw your question. Please press star one again, please be advised that today's conference is being recorded.
Speaker Change: I'd now like to hand, the conference over to your Speaker today Christian O'donnell, Vice President of Investor Relations. Please go ahead.
Christian O'Donnell: Thank you operator, good morning, and welcome to Lam Core's first quarter 2025 conference call as detailed in today's press release, there will be a replay of this conference call available with me today are Adam Schechter, Chairman and Chief Executive Officer, and Julia Wong Executive Vice President and Chief Financial Officer. This morning in the <unk>.
Christian O'Donnell: That's your relations section of our website at Www Dot lab, where dot com, we posted both our press release and Investor Relations presentation with additional information on our business and operations, which include a reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures.
Christian O'Donnell: Which I discussed during today's call.
Christian O'Donnell: You see the use of adjusted measures section in our press release and Investor Relations presentation for more information regarding our use of non-GAAP financial measures. Additionally.
Christian O'Donnell: Additionally, we are making forward looking statements. These forward looking statements include but are not limited to statements with respect to the estimated 2025 guidance and related assumptions the projected impact of various factors on the Companys business is operating and financial results cash flows or financial condition, including global Hawk.
Christian O'Donnell: And market conditions future business strategies expected savings benefits and synergies from the Launchpad initiative and from acquisitions and other strategic transactions and partnerships. The completed holding company reorganization and opportunities for future growth each of the forward looking statements are subject to change based upon various.
Speaker Change: Actors many of which are beyond our control more information is included in our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q and in the Companys other filings with the S. E. T. We have no obligation to provide any updates to these forward looking statements, even if our expectations change now I'll turn the.
Adam Schechter: Call over to Adam Schechter.
Adam Schechter: Thank you Kristen and good morning, everyone. We appreciate you joining us today to discuss our first quarter 2025 financial results and progress towards advancing our strategic priorities.
Adam Schechter: Performance in the first quarter was solid with 5% revenue growth or 6% on a constant currency basis across the enterprise.
Adam Schechter: The performance was driven by 6% growth in our diagnostics laboratories business, where there was a strong rebound in volume in March after impact from weather in January and February.
Adam Schechter: Our strong managed care access and our payer contracts continue to serve us well in the marketplace.
Adam Schechter: Adjusting for <unk> and whether the margin in the diagnostics business improved 50 basis points.
Adam Schechter: If we take continues to perform very well.
Adam Schechter: It remains on track to achieve 10% revenue growth and to be slightly accretive to earnings for the full year.
Adam Schechter: Our Biopharma Laboratory services segment grew 3% excluding currency.
Adam Schechter: Margin for BLS was strong.
Adam Schechter: 80 basis points in the quarter book to Bill was also strong at 1.13 with the trailing 12 months of 1807.
Adam Schechter: Adjusted earnings per share of $3 84.
Adam Schechter: We're up 4% year over year.
Adam Schechter: It is certainly a very dynamic environment and our team is closely evaluating the ongoing shifts in the macroeconomic and regulatory landscapes.
Adam Schechter: We're pleased with the outcome of the court's decision and.
Adam Schechter: The challenge of the <unk> rule.
Adam Schechter: We believe it's in the best interest of bringing new innovative tests to patients as quickly as possible.
Adam Schechter: We are also contingency planning for various tariff and regulatory scenarios.
Adam Schechter: We have developed duplicative flexible supply chains.
Adam Schechter: And we are in communications with our customers and suppliers.
Adam Schechter: While we do anticipate some impact.
Adam Schechter: Our guidance range includes what we believe to be the most likely scenarios at this time.
Adam Schechter: The essential nature of our work has enabled us to be successful through many different economic cycles over time and.
Adam Schechter: And we will continue to focus on serving the needs of our customers and driving growth.
Adam Schechter: While delivering value for shareholders as we advance our mission to improve health and to improve lives.
Adam Schechter: Based upon our performance and outlook, we have reaffirmed our revenue and free cash flow guidance, while increasing the midpoint of our EPS guidance by <unk> five per share with the implied growth at the midpoint of approximately 10% for the year.
Adam Schechter: We also continue to expect margin expansion in each segment for the full year.
Adam Schechter: Julia will provide more details on our results and the 2025 outlook in just a moment.
Adam Schechter: We continue to execute well on our strategic priorities of being a partner of choice for health systems, a regional local laboratories.
Adam Schechter: Launching new tests, it important high growth therapeutic areas.
Adam Schechter: By Harnessing science innovation, and advanced technology to bring valuable services and capabilities to our customers, while improving operational efficiency.
Adam Schechter: In the first quarter Labcorp became the partner of choice for several health systems, a regional local labs.
Adam Schechter: These partnerships enable us to accelerate growth.
Adam Schechter: To expand you into important geographies and therapeutic areas.
Adam Schechter: In January we announced a strategic collaboration with New Jersey based inspire how to manage the operations of the health systems Hospital laboratories and.
Adam Schechter: And to serve as the primary lab for the physician network.
Adam Schechter: In March we announced an agreement to acquire select assets of bio reference house oncology and related clinical testing services.
Adam Schechter: This transaction will extend our leadership in oncology.
Adam Schechter: We also completed the acquisition of select assets of North, Mississippi Health services ambulatory outreach laboratory business and we became a referral app, we're at seven hospitals and clinical laboratories.
Adam Schechter: Looking ahead, we have a strong business development pipeline and we look forward to sharing additional growth opportunities with you.
Adam Schechter: Coming quarters.
Adam Schechter: We also continue to incorporate the power of science of innovation kind of advanced technology across the organization.
Adam Schechter: We're focused on bringing new tests into four strategic areas encore.
Adam Schechter: <unk> women's health autoimmune disease and neurology.
Adam Schechter: These areas have significant unmet needs for patients and are expected to grow up to three times faster than other therapeutic areas and they are proving to do so.
Adam Schechter: Having the latest innovative tests in these areas enables us to successfully capture more value across testing for those patients.
Adam Schechter: For example in the quarter, we introduced Labcorp plasma complete.
Adam Schechter: A groundbreaking liquid biopsy test to aid in personalized cancer treatment decisions.
Adam Schechter: This advancement significantly experience labcorp extensive ecology portfolio.
Adam Schechter: We made significant strides, bringing <unk> genetic testing solutions to our customers by launching patient affordability and access tools a.
Adam Schechter: By introducing two additional genetic risk panel test.
Adam Schechter: Labcorp Ondemand launched several new consumer initiated tests.
Adam Schechter: Excluding electrolyte GTT hepatitis, a and total testosterone for women.
Adam Schechter: Subsequent to the quarter, we introduced HPV and STI self collection options and Labcorp patient service centers and physician offices.
Adam Schechter: These solutions help overcome barriers to a central health screening by providing convenient private testing options.
Adam Schechter: And in April.
Adam Schechter: We launched our P Tau beta amyloid ratio test.
Adam Schechter: A powerful new blood based biomarker test to aid in the diagnosis of Alzheimer's disease.
Adam Schechter: This first of its kind immunoassay <unk>.
Adam Schechter: Further expands our leading portfolio for all simers disease and dementia.
Adam Schechter: Launching tests in these important areas will enable us to outpace the growth in the overall market over time.
Adam Schechter: We're also using AI and technology to enhance our customer experience and to bring forward new operational efficiencies to improve our margins.
Adam Schechter: For example earlier this month.
Speaker Change: <unk> received a modern healthcare 2025 innovators award for Labcorp diagnostics assistant.
Speaker Change: A digital solution integrated into electronic Health Records.
Speaker Change: Supports providers real time access to comprehensive laboratory data insights and self service capabilities.
Speaker Change: This award recognizes us as a leader in driving innovation that improve care and achieved measurable results.
Speaker Change: We also launched E claim assessed a next generation digital platform that introduces smarter workflows to improve efficiencies and billing.
Speaker Change: Payer alignment and denials.
Speaker Change: We will continue to find operational efficiencies through technology.
Speaker Change: All aspects of our business.
Speaker Change: Lastly, we released the Labcorp corporate responsibility report.
Speaker Change: Which highlights our significant progress in key areas, such as reduced water withdrawal and.
Speaker Change: And improved fuel efficiency.
Speaker Change: We invite you to review the report on our Investor Relations website.
Speaker Change: In summary.
Speaker Change: Our business continues to perform well and.
Speaker Change: And we are making strong progress against our strategy.
Speaker Change: We believe that Labcorp will continue to be successful and will lead the way with a relentless focus on science innovation and advanced technology.
Speaker Change: We remain committed to providing value to our customers and our shareholders alike.
Julia Wong: With that I'll turn the call over to Julia.
Julia Wong: Thank you Adam let me start with a review of our Q1 financial.
Julia Wong: Revenue for the quarter was $3 $3 billion a year.
Julia Wong: With a five 3% compared to last year.
Julia Wong: Driven by organic growth of two 1% and the impact from net acquisitions of three 7%.
Julia Wong: Partially offset by foreign currency translation of 5%.
Julia Wong: Operating income for the quarter was $326 million or nine 7% of revenue which is 14%.
Julia Wong: A basin.
Julia Wong: During the quarter, we had $73 million of restructuring charges and special items.
Julia Wong: Not really related to amortization in announced savings.
Julia Wong: Excluding these items amortization of 17 <unk>.
Julia Wong: Operating income in the quarter was $469 million.
Julia Wong: 14% of revenue.
Julia Wong: <unk> two $453 million of 14, 3% of revenue last year.
Julia Wong: The increase in our adjusted operating income was primarily due to demand in announced savings.
Julia Wong: <unk> offset by higher personnel costs.
Julia Wong: The 20 basis point decline in our adjusted operating margin, including the headwinds from <unk> and the weather excluding Lake enterprise margins would have been up 60 basis points.
Julia Wong: The adjusted tax rate for the quarter was 22, 5% compared to 23% last year.
Julia Wong: We continue to express our adjusted tax rate for full year 2025 to be approximately 23%.
Julia Wong: Net earnings for the quarter were $213 million or $2, 60% plus the ability to share.
Adjusted EPS was $3 84 in the quarter, 4% from last year.
Julia Wong: Operating cash flow was $19 million in the quarter compared to a use of $13 million a year ago.
Julia Wong: The increase in cash flow was primarily due to the timing of working capital.
Julia Wong: Capital expenditures totaled $126 million in the quarter.
Julia Wong: For the full year, we continue to expect capital expenditure to be approximately eight 8% revenue.
Julia Wong: Free cash flow for the quarter was a use of $180 million compared to a use of $164 million last year.
Julia Wong: So first quarter is typically the company.
Julia Wong: Therefore free cash flow.
Julia Wong: We continue to expect a free cash flow for the full year to be $1 $1 billion to $105 million.
Julia Wong: During the quarter the company invested $211 million.
Julia Wong: Patients in the partnership.
Julia Wong: And paid out $62 million in dividends.
At quarter end, we had $369 million in cash while total debt was $5 $6 billion.
Julia Wong: Our debt leverage as of quarter end was two five times gross debt to trailing 12 month adjusted EBITDA.
Julia Wong: At the low end of our targeted leverage of two five times to three times.
Speaker Change: Now I will review our segment performance beginning with diagnostics laboratory.
Speaker Change: Revenue for the quarter was $12 $6 billion.
Speaker Change: The increase of 6% compared to last year.
Speaker Change: With organic growth of one 6% and net acquisitions of four 7%.
Partially offset by foreign currency translation of 0.3%.
Speaker Change: Organic growth was impacted by approximately 190 basis points from weather and one fewer revenue Bay, which is timing related within the year.
Speaker Change: Total volume increased 3% compared to last year as the organic volume contributed zero plus 9%.
Speaker Change: While acquisitions net of divestitures contributed 12, 1%.
Speaker Change: Organic volume also includes the negative impact from weather and one fewer revenue days.
Speaker Change: Price mix increased 3% versus last year, if organic growth of 0.7% and acquisitions net of divestitures of two 6%.
Speaker Change: Partially offset by foreign currency translation of <unk>, 3%.
Speaker Change: Organic price mix was up due to mix as we benefited from a yen Christine press, a button and lab management agreement.
Diagnostics adjusted operating income for the quarter was $428 million or 16, 3% of revenue.
Speaker Change: Compared to $418 million or 16, 9% of revenue last year.
Speaker Change: Adjusted operating margin was down 60 basis points due to maintain the weather.
Speaker Change: Excluding this item adjusted operating margin would have been up approximately 50 basis points as.
Speaker Change: As the benefit help organic demand in announced savings was partially offset by higher personnel costs.
Speaker Change: Ladies remains on track to be slightly accretive for full year 2025.
Speaker Change: Now I will review the segment performance of Biopharma Laboratory services or BLA.
Speaker Change: Revenue for the quarter was $721 million, an increase of one 5% compared to last year.
Speaker Change: Why are you increasing your organic revenue up two 6%.
Speaker Change: Partially offset by foreign currency translation of one 1%.
Speaker Change: Excluding currency early development revenue growth was approximately 5%.
Speaker Change: While central lab revenue growth was approximately 2%.
Speaker Change: As expected the central lab growth rate it was low in Q1 2025.
Speaker Change: We had a large amount of COVID-19 vaccine and therapeutic revenue in Q1 of 2024.
Speaker Change: Our segment quarterly book to Bill was strong at 113.
Speaker Change: During the trailing 12 months book to Bill to one seven.
Speaker Change: <unk> as adjusted operating income for the quarter was $107 million.
Speaker Change: 14, 8% of revenue compared to $100 million of 14, 1% of revenue last year.
Speaker Change: Adjusted operating income and margin increased due to organic demand and allowance Pep savings.
Speaker Change: Partially offset by higher personnel costs.
Speaker Change: We ended the quarter with a backlog of $8 2 billion.
Speaker Change: And we expect approximately $2 $6 billion of debt.
Speaker Change: This backlog to convert into revenue over the next 12 months.
Speaker Change: Now I will discuss our updated 2025 and full year guidance.
Speaker Change: <unk> assumes foreign exchange rates effective as of March 31, 2025 for the remainder of the year.
Speaker Change: The enterprise guidance also includes the impact from current today on pace repatriated capital allocation.
Speaker Change: The licensing for a crush flow for acquisition sure.
Speaker Change: Repurchases and dividends.
Speaker Change: We are operating in a dynamic macro environment and there are a series of regulatory developments that we continue to monitor closely.
Speaker Change: Our guidance has taken into account the various scenarios of the Albertsons in Paris, and the regulatory landscape.
Speaker Change: Based on what we believe to be the most likely scenarios.
Speaker Change: Time, and the resilience of our businesses.
Speaker Change: We are reaffirming our enterprise revenue and free cash flow guidance, while raising the midpoint of adjusted EPS.
Speaker Change: Enterprise revenue growth guidance remains six 7% to 8% compared to 2024.
Speaker Change: Diagnostics continues to perform well consistent with prior guidance, we expect the diagnostics revenue to be up six 5% to seven 7% compared to 2024.
Speaker Change: We still expect that BLS revenue to grow 3% to 5% compared to 2024.
Speaker Change: This includes the negative impact of 30 basis points from foreign currency.
Speaker Change: Prior guidance included a negative impact of 100, and a 40 basis points.
Speaker Change: We continue to expand the enterprise margins to be up with modest improvement in both diagnostics and the BLS in 2025 worth of 2024, driven by top line growth and allows for that savings.
Speaker Change: Our guidance range for adjusted EPS is $15 and the 72 was $16 in the fourth he said was.
Speaker Change: Was that your implied growth rate at the midpoint of 10%.
Speaker Change: As compared to prior guidance, we have narrowed the range and raised the midpoint by five.
Speaker Change: Our free cash flow guidance range is $1 1 billion to $1 $205 billion.
Speaker Change: All trends from prior guidance.
Speaker Change: Due to normal seasonality, we expect it to be weighted towards the second half of the year.
Speaker Change: In summary, we had a solid first quarter with a dynamic macro environment.
Speaker Change: We expect to drive continued profitable growth and strong free cash flow generation that will be used for acquisitions that support our strategy and supplement our organic growth.
Speaker Change: While also returning capital to shareholders through our share repurchase program and dividends.
Speaker Change: Operator, we will now take questions.
Speaker Change: Thank you as a reminder.
Speaker Change: Jen Please press star one on your telephone and wait for your name to be announced to withdraw. Your question. Please press star one again, please standby, while with Japan, the Q&A roster.
Speaker Change: Yeah.
Speaker Change: And our first question comes from Michael Cherny of Leerink Partners. Your line is open.
Speaker Change: Good morning, Michael.
Michael Cherny: Good morning, Adam. Thank you so much for taking the question.
Speaker Change: Just I'll just have one here and it's tied to the BLS segment on both Central lab and early development, obviously, theres a lot of noise and volatility tied to the changing administration type of changes at the FDA as you progressed through the quarter and as you think about what's embedded in your guidance now how much variability versus.
Speaker Change: <unk>, what you would expect to be normalized demand is incorporated there and are you seeing any feedback on either central lab, our early development.
Speaker Change: <unk> relative to awards to starts based on the uncertainty that's clearly been created by the current administration.
Michael Cherny: Yes. Thank you for the question Michael.
Speaker Change: Start off with if you look at the Pls business, we had about three.
Speaker Change: <unk>, 3% growth overall, and it was about 2% and CLS and about 5% in.
Speaker Change: Early development and what we saw was continued strength in the book to Bill. So the book to Bill actually it was a $1 one three for the.
Speaker Change: For the quarter and the trailing 12 months increased to one seven so we feel good about where we are right now when you look at the range that we gave for the revenue, we gave 3% to 5%, which at the midpoint of 4%.
Speaker Change: Could've said well with exchange why did you not increase the range. The reason, we didnt increase the ranges because there is some unknowns in the landscape to which you acknowledged and brought up so we wanted to give ourselves room within the range.
Speaker Change: If foreign exchange stays right, where it is today and we didn't see any additional impact from some of the things in the macro environment will end up at the high end of the range the highest.
Speaker Change: If we see some of these other things like a delay and study starts due to getting regulatory information in a timely way.
Speaker Change: And that could bring us more towards the midpoint of the range or maybe below the midpoint of the range. So we feel like with the range that we gave it takes into account the various different things that could occur within the landscape with the midpoint being what we think is most likely so I really believe that we have room within our range for things that could occur as we sit here today.
Speaker Change: We have not seen study delays, we have not seen studies that have not progressed we.
Speaker Change: One larger cancellation for Covid trial, and our book to Bill.
Speaker Change: But you can see from our strength of our book to Bill we more than overcame that one trial, but other than that it seems to be steady as we go at the moment, but we'll continue to monitor it is a very fair.
Speaker Change: Fast moving environment, but I feel good about where we are and what the ranges.
Speaker Change: Okay.
Speaker Change: Thank you.
Speaker Change: And our next question comes from Ann Hynes from Mizuho. Your line is open.
Ann Hynes: Hi, good morning so.
Ann Hynes: Saying that you have tariffs now embedded in guidance, which I don't believe was in the original guidance can you, let us know how much tariffs now are embedded in guidance and then Mr.
Ann Hynes: That implies the underlining operation is doing better than your initial expectations.
Ann Hynes: Yeah. Thanks, John So as I think about the tariffs first of all I'd say, we are well positioned and we expect to continue to deliver on the commitments that we put forward.
Ann Hynes: First and foremost, we built duplicative and flexible supply chain that I think really helps that improves our resiliency.
Ann Hynes: There will be some impact from the tariffs, but our guidance range includes what we think are the most likely scenarios, but just to give you some context and so the vast majority of our vendor spend is from U S companies, where we're not the importer of record.
Ann Hynes: You looked at our contractual arrangements with secured pricing it represents more than 80% of our span. Many of these deals are multi year contracts. So some of them come up every year for renewal, we're going to work on our supplier community, we're going to negotiate hard and accordingly.
Ann Hynes: If you look at like items that we buy directly from countries like China, the mostly plastics consumable supplies stuff like that but it's minimal today and we are looking to shift to more favorable countries as best we can and I think we have a pretty good path forward for that if you look at Biopharma and you look at central Labs in particular.
Ann Hynes: There is some impact from keeps moving in and out of the United States, but a lot of that's transportation and a lot of those costs can be typically.
Ann Hynes: Typically put through pass throughs, which is going to help us manage it so as I look at the range of different possibilities within what we think are most likely scenarios through continued expense focus continue.
Ann Hynes: <unk> focus on our operations, we think we'll be able to offset the impacts from the tariffs and that's why we felt comfortable with the guidance that we gave for revenue of six 7% to 8%.
Ann Hynes: With a midpoint of seven 5% and holding to that and we feel comfortable and actually raised the bottom end of our adjusted EPS based upon that strength.
Speaker Change: Great. Thanks.
Ann Hynes: Thank you.
Erin Wright: And our next question comes from Erin Wright of Morgan Stanley. Your line is open.
Speaker Change: Good morning, Eric.
Eric: Good morning.
Speaker Change: Could you break down a little bit in terms of your expectations on underlying organic growth across the diagnostics business for the balance of the year, how much is from acquisitions versus organic and has anything changed in terms of your expectations. There in terms of underlying utilization trends and if I could also ask more of a housekeeping one but how did that weather.
Eric: The impact of <unk> <unk>.
Eric: Previously alluded to actually shake out relative to your expectations.
Speaker Change: Yes, thanks, Terence so in general, we still expect about half to come from organic and inorganic.
Julia Wong: You look at the first quarter organic growth was one 6%, but if you just adjusted for weather and the revenue would have been three 5% and therefore I think it would be more what you would expect typically Julia if you want to provide some additional context there.
Erin Wright: Hey, good morning Erinn.
Julia Wong: We were pleased with our results for the diagnostics business in the first quarter.
Julia Wong: We grew revenue about 6% in the quarter once a year ago, which was supported by strong volume growth of 3%.
Julia Wong: Ruble price next young pact of 3%.
Julia Wong: Adam just sure if you were to neutralize the unfavorable impact of additional weather as well as the one less revenue day.
Julia Wong: Organic revenue in the quarter.
Julia Wong: Well above 3%, which was in line with our historical trend as well as our expectation going forward for 2025.
Julia Wong: Can you just to anchor ourselves, okay organic revenue growth reported in the quarter of one 6%, although nickel volume was seven 9% of our growth. Once again that was impacted by one less revenue day and whether the organic price mix was up zero point.
Julia Wong: 7%, primarily due to higher test pilot session and increased national agreements.
Julia Wong: If you neutralize the impact of weather as well as the one that's revenue day, the volume price mix gross contribution will be approximately three to one ratio once again in line with our historical trend no.
Julia Wong: Looking forward, we are pleased about the trajectory of your making integration whilst events as I've shared in the prepared remarks, we continue to expect that business to be slightly up cases.
Julia Wong: For full year 2025, and we will have reaffirmed revenue guidance for the full year for diagnostics to be between six 5% to seven 7%.
Julia Wong: And we look forward to expanding the margin for the business as well what does Tobey Tobey four which will contribute to our expectation that we will look to expand the enterprise margins for 2025 Watts has plenty of total fall as well.
Speaker Change: Great and if I could ask a follow up on the policy Bryan and regulatory front, we obviously got the LBP.
Speaker Change: Favorable will there, but on Pan line, Firstly, Panama grow form what are what are your latest thoughts in terms of timing and magnitude. Obviously this is degrees of positive from the original payment methodology, but how big of a difference will that be.
Speaker Change: Yeah. So first of all we're very pleased with the court ruling.
Speaker Change: Regarding <unk> as I said before it wasn't a significant impact to us in terms of revenue nor expense because we were doing a lot of the work by submitting to New York State already but I felt that it would really impact innovation and getting tests to patients as quickly as possible. So I think that.
Speaker Change: We ended up in a good place there.
Speaker Change: I think it would enable us to meet patient needs in the marketplace as I look at <unk>.
Speaker Change: For the last five years, we've been trying to get legislation in place that makes more sense than the current legislation and we have support from our public is and Democrats and we've had that for five years now, but unfortunately, we havent gotten legislation through which has led to each year a delay.
Speaker Change: We will work with our trade group ACL as to continue to see if theres better legislation that can be passed.
Speaker Change: We will continue to work hard to see if that can be done at the same time, we will try to find ways to look for additional delays, but I continue to put in our base case that each year. The next year Pamela will come so I assume in January of next year there'll be an impact from Panama.
Speaker Change: The impact to be around $100 million for the full year and we'll build a plan that makes us successful. Despite that if you look at our three year guidance that we provided a bit ago that included an impact from Panama. So we have always anticipated that in our base case that would be coming.
Speaker Change: And planning around that so we will continue to do so, but we'll do everything in our means to get better legislation passed or to get another delay.
Speaker Change: Okay, great. Thank you.
Speaker Change: Thank you.
Elizabeth Anderson: And our next question comes from Elizabeth Anderson of Evercore ISI. Your line is open good morning.
Adam Schechter: Good morning, Adam Thanks, so much for the question.
Adam Schechter: You guys mentioned, a couple of times higher personnel costs in the quarter and I. Just wanted to clarify is that something that youre sort of seeing overall or was that specifically a function of the revenue sort of debt and cost day impact in the quarter.
Adam Schechter: Any one timers just to point out on the <unk> that you would call out right now thank you.
Adam Schechter: Yes. Thanks, so when we talk about higher personnel costs assist the inflation of personnel, which we expect every year to be three to three 5% and we work hard with our Launchpad initiative to offset that so nothing other than what would be typical in a normal range of.
Adam Schechter: Higher personnel costs due to inflation.
Speaker Change: Okay. That's super helpful and any one time items, you would call out so far particularly impacting the <unk>.
Adam Schechter: Outlook.
Adam Schechter: Alright.
Adam Schechter: Okay perfect.
Adam Schechter: Nothing nothing to call out great.
Adam Schechter: Great. Thanks.
Adam Schechter: Thank you guys.
Adam Schechter: Now, let's take volume continues to perform well into April.
Adam Schechter: Which continues the strength of what we saw in March So we are there.
Adam Schechter: We're encouraged by that.
Speaker Change: Okay, great. Thank you.
Adam Schechter: Okay.
Speaker Change: And our next question comes from Lisa Gill of Jpmorgan. Your line is open good morning.
Adam Schechter: Lisa.
Lisa Gill: Good morning, Adam and Juliet Thanks for taking my question.
Lisa Gill: And then I just want to go back to your earlier comments, when we think about potential changes on the FDA side.
Lisa Gill: Then some talk on the early development side of the business around animal testing can you maybe just remind us.
Lisa Gill: In early development, how much of that business is today with animal testing and if that were to change what the potential impact would be.
Lisa Gill: Yes.
Lisa Gill: Part with some context, Liza and then ill provide some additional information so as we look at non animal testing, we have always said that as soon as the market can move to that will be very supportive in fact, we have about 90.
Lisa Gill: Ph D as our Mds and are working all day every day to try to find non animal models to move forward with <unk>.
Lisa Gill: As we think about that that will become a bigger business over time, and we want to be part of that business over time.
Lisa Gill: Of course, we'll continue to work with regulators and we're committed to complying with all regulatory compliance guidelines and the research that we conduct.
Lisa Gill: There is currently no full replacement for animal models and research and development that we're aware of.
But we're going to continue to work to find ways to do that so there is no doubt that any new guidance would have to be implemented over time of which we will collaborate.
Lisa Gill: Work with the folks over time, when you look specifically about the animal testing that they were looking at.
Speaker Change: <unk> monoclonal antibodies in the beginning that's roughly 10% 15% of our total revenue. So it's not a big piece of our Pos business.
Speaker Change: For other parts to move to non animal models is just going to take a lot longer. So I would summarize it to say, we don't expect any significant impact. This year, we're going to work on non animal models with regulators as soon as they're ready we're ready we want to be part of that business into the future and if monoclonal antibodies, where the first place.
Speaker Change: To move then it would not be that big of an impact of our total business.
Speaker Change: So just just go I understand that so it would be 10% to 15% of the operating profit of BLS and so if I think about it for the total enterprise it would be single day that right is that the way to think about it.
Speaker Change: So that's the revenue and operating profit will be less than that and then very small very very small in terms of the total revenue for the company.
Speaker Change: Perfect. Thank you so much sir.
Speaker Change: Thank you.
Speaker Change: And our next question comes from Jack Meehan of Nephron Research. Your line is open good morning Jack.
Speaker Change: Good morning.
Jack Meehan: I hope you're doing well.
Speaker Change: Wanted to follow up on your comments around <unk>.
Speaker Change: <unk> traction toward getting to accretive slightly.
Speaker Change: Slightly accretive for the year.
Speaker Change: In the quarter I think the Matthew laid out implied between retired whether it was about a 30 million EBIT impact to the <unk> segment.
Speaker Change: I was wondering if you could maybe tie had been around 20 million and then maybe just talk about like how do you get that to be a positive number later in the year.
Julia Wong: Yes, so I think assessing that but I'll have Julia talk about that specific I just wanted to give some context to it <unk>. The integration is going very well in fact, I would argue it's probably even better than what I had even anticipated and we continue to make a lot of progress as we think about the full year, we still expect the Rev.
<unk> growth is going to be over 10% and we've said that we believe women's health autoimmune disease oncology and neurology represents opportunities to have outpaced growth versus the overall diagnostic market. We believe that this is a piece of that and this is another proof point to show that when Youre enrolment.
Julia Wong: Alright ecology, you can get faster growth. So I feel very good about the revenue I feel very good about the integration we remain on track to have an <unk> accretive for the full year and when you look at the way in which we've gone after the expenses we've been very methodical.
Julia Wong: So we've taken the best of the best approach, we take the best Science the best.
Julia Wong: Customer interactions from either Labcorp VK and then we apply it across the organization. So it's taken us a little bit longer to get the cost out that we took.
Julia Wong: Typically we would see.
Julia Wong: It's going very well and Thats why I have caused us to reiterate that we believe it will be accretive.
Julia Wong: For the full year.
Julia Wong: Yeah, the only additional color.
Julia Wong: Ed.
Julia Wong: As to the.
Julia Wong: Impacting the quarter. So what we said it was if you look at our enterprise.
Julia Wong: The quarter.
Julia Wong: You saw a 20 basis point decline versus a year ago as the Mr. July with a combination of <unk> and whether when you exclude those two items. The enterprise margins would have been up about 60 basis points.
Julia Wong: And then reiterated earlier our expectation is as we progress. So after 2025 youll start to seeing EMEA page 15 from a loss to our patients, particularly in the second half so much that for the full year, we expect <unk> to be slightly accretive.
Julia Wong: Yes.
Julia Wong: That is the impact of filmmaking.
Julia Wong: Okay. Thank you.
Speaker Change: And then maybe as a follow up just on lab M&A.
Speaker Change: How do you how would you characterize the environment right now and you have leverage at two five times youre integrating a lot of deals you've done over the last year.
Speaker Change: Just how should we expect kind of the pace of activity.
Speaker Change: Without the rest yes. Thank you so I would say the pipeline remains very strong.
Speaker Change: I would say with some tariff implications to hospital systems as well as some of the other things they could be facing in the macroeconomic landscape.
Speaker Change: We are seeing more outreach to us to actually have discussions as you recall some of these discussions take a very long time some of them go.
Speaker Change: A shorter time than others, but over time the pipeline looks really good.
Speaker Change: I would expect we'll have more to share with you as we go through each quarter this year.
Speaker Change: Okay. Thank you guys.
Speaker Change: Thank you.
Speaker Change: And our next question comes from Luke <unk> of Barclays. Your line is open.
Speaker Change: Luke.
Speaker Change: Thank you just wanted to dig in a little bit on the diagnostics operating margin expansion just kind of laid out there from a detailed but I was hoping you can.
Speaker Change: Dig in there a little bit on kind of the puts and takes or bucket out the individual components for what's driving that that our Max for the year. So you talked a little bit on <unk>, but if you could talk about like how the recent M&A contributes maybe in some of the tariffs or tariff offsets.
Speaker Change: Core improvements from the claims youre pricing mix, just kind of the underlying assumptions.
Speaker Change: Based on that on that assumption.
Speaker Change: Yes, so I'll start with if you look at the operating margin for our diagnostics was down 60 basis points that was due to a VK, whether if you adjust for that it would have been up 50 basis points.
Speaker Change: We still expect margins to actually be up this year versus last year. When you look across the year. So that tells you we see strength in the diagnostic business margins as we go through the year a lot of that is the overlap of in VITAS. Once we overlap that and it becomes accretive it actually helps us with the margins.
Speaker Change: Overall, the second thing is we continue to focus on our launchpad initiatives, where we take out between $125 million and a lot of that still comes out of the diagnostic business. So we continue to see benefit there and we're continuing to see some benefit from mix in terms of esoteric testing as well.
Speaker Change: All of those things give us.
Speaker Change: The reason that we expect the margins to increase and get better as we go through the year.
Speaker Change: Great and then just a follow up here and go back to the BLS booking strength.
Speaker Change: There's the overhang or the thoughts from pharma tariffs coming on.
Speaker Change: Initiated another round of restructuring just interested in what you guys are hearing from your various customer bases across biotech large pharma, how they're thinking about the tariff in and if there is do you think that there is more.
Speaker Change: Pipeline rationalize our R&D cuts.
Speaker Change: There is still.
Speaker Change: That could be on the come.
Speaker Change: So as I look at that I looked at our Central Laboratory business first and I looked at our Central Laboratory. Most of that is phase II phase III trials and I think that's the last place pharma would ever go to reduce cost because the phase II phase III is the future growth of future pipeline. So I feel good about it.
Speaker Change: Pipeline as I looked at the CLS and I looked at the book to Bill We continue to have good rfps in early development. Our win rate continues to do well and the book to Bill continues to look good but that scenario well have to continue to watch closely because I think that could be impacted more by some of the things that you mentioned over time.
Speaker Change: But where we have and we continue to work towards getting a larger mix of business in early development from mid to larger sized pharma and I think as we shift that mix it will serve us well over time as well.
Speaker Change: Great. Thanks.
Speaker Change: Yeah.
Speaker Change: Thank you.
Speaker Change: And our next question comes from Kevin Caliendo of UBS. Your line is open.
Speaker Change: Good morning, Kevin.
Speaker Change: Good morning, Adam Good morning, Juliet Thanks for taking my question.
Speaker Change: I wanted to.
Speaker Change: Talk a little bit about the margin in diagnostics again, just a little bit further I know you've touched on it a bit here. If we think about the first quarter 60 basis points net of in.
Speaker Change: <unk> being better 60 basis points net of <unk> net of weather is the weather number a net number or just the number for the quarter, because presumably there was weather and <unk> 24 as well right.
Speaker Change: Number yes, it's another number Kevin yes fantastic at Super helpful. So then if I think about.
Speaker Change: What's going on and the fact that March the strength in March goes into April as Julian mentioned, and we think about the improvement in margin year over year for <unk>, because I don't think there was any weather comp or anything else in <unk> should we should be thinking about a year over year margin improvement with <unk> getting a little bit better that.
Speaker Change: Maybe you could.
Speaker Change: Is that 60 basis points out of the baseline on a year over year basis that we'd be thinking about for <unk>.
Speaker Change: And is that like a progression over the year is that how we should think about it net net.
Speaker Change: Yes. So thank you for the question.
Speaker Change: Don't guide to the quarter, but the last Q&A soft process is reasonable take today do you see Q2 being a strong quarter.
Speaker Change: Definitely from a topline standpoint, and then to your point as we continue to make progress toward.
Speaker Change: <unk> should be treated with it that would help the overall margin for the diagnostics business in particular.
Speaker Change: Profits once again.
It's within the mall.
Speaker Change: Fantastic. Thank you very much.
Speaker Change: Thank you.
Michael Riskin: And our next question comes from Michael Riskin of Bank of America. Your line is open.
Speaker Change: Hey, Michael.
Michael Riskin: Good morning, Thanks for the question Adam.
Michael Riskin: Just wanted to go back to your comments earlier a little bit.
Michael Riskin: A reduction in FX headwind, but you're sort of absorbing that give us some of the macro uncertainty I think that certainly makes sense, but.
Michael Riskin: You haven't seen anything yet obviously, you talked about the strong book to Bill in the first quarter. It doesn't seem outside of that Covid contract that you've called out but you have seen any weakness.
Michael Riskin: Sort of how did you approach that.
Michael Riskin: That reset in guide.
Michael Riskin: Is there anything thats come up in conversations with customers and I guess sort of what are you monitoring as you go through the year to assess the health of that end market is it.
Michael Riskin: Is it the evolution of tariffs this is something on the policy front.
Michael Riskin: As a biotech funding just sort of walk us through what you see is the leading indicators there.
Speaker Change: No. Thanks for the question I wanted to provide some context to the BLS business in particular with the Central Laboratory business. So we had expected that the first quarter will be the lowest growth rate when we compared to the remainder of the year.
Speaker Change: And the reason that was because we saw strength in the first quarter of last year. If you go back to first quarter 2023. We show. We saw some are 20 to 34, we saw some real strength.
Speaker Change: Within that strength was about $18 million of Covid vaccine and therapeutic breadth.
Speaker Change: That was about the same frankly as the first quarter of 2020.
Speaker Change: First quarter 'twenty 'twenty four is about the same as first quarter 'twenty three.
Speaker Change: 45, we had virtually zero COVID-19 related work. So it's not a big Delta when you compare that to the broader CLS business, but it gives you a sense of the underlying growth rate and impact so as I looked at the Pls business. The first quarter, we expect it to be the toughest compared to last year.
Speaker Change: As I look at the rest of the year, we continue to expect.
Speaker Change: Business to grow better and Thats, why we feel confident in the 3% to 5% guidance range. The reason we didn't raise that range based upon current Forex is for multiple reasons that we can see pushes and pulls what im looking for is do the trial start on time, we expect the trial to <unk>.
Speaker Change: They have up until now, but we've heard some noise about how fast people are getting regulatory inputs to some of their trials and we wanted to make sure that the trials startup time that they get the inputs that they need.
Speaker Change: In order to start this trial sometime so we're going to watch that very carefully we'll watch the impact of tariffs and do people change where they're running some of these trials in different parts of the world is do we have to make some adjustments. So we'll watch that as well and then we'll continue to watch our early development business, where up until now the signs of stress.
Speaker Change: Well, we're going to watch that for biotech funding and so forth. So the reason we didn't change the range is because I believe that if forex stayed where it was today and everything continues to go well we'd be at the highest end of that range.
Speaker Change: Things get a little bumpy in terms of timing of trials starts hopefully, it's going to impact whether the trials go on or not but it could impact the timing well then it could bring you back more towards the midpoint foreign exchange could change we've seen it would be very dynamic in the marketplace. So we didn't want to make a change based on fund Forex that we've seen.
Speaker Change: Bumping up and down so fast in the marketplace. So for all those reasons, we felt confident to confirm the 3% to 5% guidance range with the 4% midpoint.
Speaker Change: Okay. That's really helpful. Appreciate that color just a quick follow up on that any change in your expectations on pricing.
Speaker Change: Or have you had any early conversations on maybe customers being a little bit more price sensitive.
Speaker Change: The customers are always going to be price sensitive I think with some of the issues that everybody is facing we're all more price sensitive than we are today, we're being harder on our suppliers than we typically Ken and I would expect that our customers will be hard enough as well.
Speaker Change: But with all that said as we sit here today most of our business is a backlog driven business where the.
Speaker Change: Studies are already under contract and so forth. So I feel pretty good about where we are as we go through this year and then we'll continue to look for ways to reduce cost and to offset any pressure that we face and that's why I feel confident not only in the guidance that we've provided with the fact that we expect that margins will improve this.
Speaker Change: This year in both the Biopharma laboratory business and diagnostic business versus last year, because we will continue to find ways to offset any of those pricing headwinds with additional cost reductions and other things.
Speaker Change: Great.
Speaker Change: Thanks.
Speaker Change: <unk>.
Patrick Donnelly: And our next question comes from Patrick Donnelly with Citi. Your line is open.
Speaker Change: Hi, Patrick good morning.
Patrick Donnelly: Hey, Adam how are you.
Speaker Change: Thanks for taking the question maybe.
Speaker Change: Maybe one I know you just talked about BLS pricing a little bit.
Speaker Change: On the lab side can you talk about the conversations there are no pricing has been a little bit more firm on your on your guys side. The tariffs change anything or are you guys, having different pricing conversations looking to pass anything on.
Speaker Change: Just curious what those conversations look like recently.
Speaker Change: Yes, so so.
Speaker Change: A lot of our business is contracted but every year. This new contracts that open up most of the contracts are multiyear contracts and the diagnostic business, but even the ones that are opening up we're still having very good constructive dialogue price has been relatively flat for us what we're looking for is to improve our volume.
Speaker Change: Which we've seen organic volume growth and we're going to continue to focus on that volume growth, but I would say we are very good.
Speaker Change: Payer access we have very good managed care access we have very constructive dialogues with the payors. So as I sit here today I feel very good about where we are and the discussions that we're having.
Speaker Change: The strength of the business overall.
Speaker Change: Okay, and then just a quick follow up on Mike's question, there on the kind of pacing of BLS and a.
Speaker Change: Lab.
Speaker Change: Basically a backlog business as you look at this year so.
Speaker Change: In terms of your answer it sounds like it's just a matter of when these trials take off their all in the backlog through some of them slip or not is going to be the delta in terms of the guidance range is that the right way to think about it.
Speaker Change: That's a big part of what we're watching like I said there was one trial that was cancelled it was COVID-19 related trial.
Speaker Change: But that's in our book to Bill and you can see the strength of our book to Bill would have been even stronger if that didn't get built.
Speaker Change: So I think COVID-19 trials, we've seen a little bit different than other trials to be Frank but we don't have many of those in a book to bill any longer it's all non COVID-19 related work. So the question to me is more of a timing issue.
Speaker Change: <unk>.
Speaker Change: <unk> get the information they need from the regulatory agencies in order to feel comfortable that their protocols will suffice in order to get approval of the product.
Speaker Change: It's not whether they will get.
Speaker Change: The comments that is how quickly will it be on time at this point, we've not seen any issues, but it's something we'll watch.
Speaker Change: Understood. Thank you guys.
Speaker Change: Thank you.
Speaker Change: Yeah.
Eric Coldwell: And our next question comes from Eric Coldwell of Baird. Your line is open.
Speaker Change: Eric.
Speaker Change: Thanks. Good morning, just a just a couple of clarifications or add ons here to other Q&A that's happened.
Speaker Change: On the Central lab Covid comp in Q1 are there additional COVID-19 comps throughout 2025% that we should be aware of.
Speaker Change: Yes, that's a great question Kevin.
Eric Coldwell: I'm sorry, Eric.
Eric Coldwell: I want to start off by saying that when I think about the Covid vaccine related works in general it's not a big number its about $18 million.
Eric Coldwell: We did $80 million last year, we did $80 million a first for the year before this year, we did virtually zero. So its just in the context of the growth rate. We thought it was good to point that out but in terms of $18 million on a base of 500 and some odd.
Eric Coldwell: So it's not a huge number as I look at the rest of this year, if I assume I have zero for the rest of this year I had about $18 million for the whole rest of last year. So it was $80 million of first quarter last year and then in the next three quarters was $18 million. So you figure for the rest of this year for zero versus $18 million.
Eric Coldwell: Spread out over three quarters last year, just to give you that context perfect. That's helpful and then.
Speaker Change: I know you've mentioned a few times the COVID-19 cancel in central lab, and you've talked about the book to Bill would've actually been better absent that of course would you care to quantify that cancellation.
Eric Coldwell: So we don't typically give numbers what I would say.
Speaker Change: It was I mean, it was larger.
Speaker Change: Slightly larger at about $100 million I'll, just give you a round number of where it was about.
Speaker Change: So a very strong book to bill excluding that.
Speaker Change: Yes, yes.
Speaker Change: Okay, and then last one thank you for all this.
Speaker Change: You've done a lot.
Speaker Change: Lot of discussion on tariffs and how you're planning to offset and absorb them, which is very encouraging I am curious if you'd be willing to give us.
Speaker Change: Ballpark gross estimate of what kind of headwind do you need to absorb as it.
Speaker Change: Is it a 1% <unk>.
Speaker Change: <unk> revenue kind of impact, 2% something less than that I'm, just trying to get a sense on how much you actually think you need to absorb at this point.
Speaker Change: Yes, I don't want to give a specific number because we have a whole range of scenarios to be honest with you and what I've done with my team if I looked at the low end that I've looked at the high end of kind of the most likely scenarios I mean, there is crazy scenarios.
Speaker Change: Take you down a path with one way or the other that we don't think are likely well within not likely scenario. What we're doing is planning for the worst of the most likely scenarios and I'm, hoping for the best and that gives me a little bit of breathing room. So what I would tell you versus others.
Speaker Change: Other industries ours is a relatively small impact because when you think about 80% of our spend being under contract and you think about the majority of our spend covered from the U S. You could get to a number that's relatively manageable under all those scenarios.
Speaker Change: Very good thanks again I appreciate it sure thanks, Sir.
Peter Chickering: And our next question comes from Peter Chickering of Deutsche Bank. Your line is now open.
Speaker Change: Good morning, Peter.
Speaker Change: I know you've got a Kieran Ryan on for Karen.
Speaker Change: Our questions good morning.
Speaker Change: I don't have much left here, but I know the I know its still pretty limited visibility, but I was just wondering if you have any thoughts or comments around.
Speaker Change: Any potential impacts to your business from some of the changes to Medicaid or ACA exchange subsidies that are being discussed.
Speaker Change: I know Medicaid and Medicare on May 10.
Speaker Change: 10% of your diagnostic revenues not very large but.
Speaker Change: Any comments you have would be helpful. Thank you.
Speaker Change: Yeah, what I would say is that if.
Speaker Change: Together they are about 10%.
Speaker Change: As I think about the business there.
Speaker Change: We have seen switching between so many different parts of the health care system or be Medicare.
Speaker Change: Manage Medicaid Medicare and we've seen lots of movement under those scenarios, we continue to do well, where I worry would be if there was a significant number of uninsured people that had to pay out of their pocket now I don't think thats likely I don't think that would be terrible for the states for the federal government, but that's where I'd be more work.
Speaker Change: We'd been seeing a shift between Medicaid Medicare managed Medicaid or going into private plans I think all of those other things are manageable and they have different pushes or pulls some you'll have more test processes.
Speaker Change: Higher price per test.
Speaker Change: Thank the pushes and pulls offset themselves to some degree.
Speaker Change: Long as people have insurance or coverage I think that in those scenarios, we do really well.
Speaker Change: Thank you.
Speaker Change: Okay.
Speaker Change: Thank you. This concludes the question and answer session I would now like to turn it back to Adam Schechter for closing remarks.
Adam Schechter: Well, thank you all for joining us today.
Adam Schechter: Look forward to discussing the business with you in the future hopefully you walk away realizing that our diagnostic business remains very strong our pls business remains strong as well and that we are committed to our patients and to our shareholders alike. So I hope you have a great day, and we'll talk to you all soon.
Speaker Change: This concludes today's conference call. Thank you for participating and you may now disconnect.
Speaker Change: Okay.
Speaker Change: [music].
Speaker Change: Okay.
Speaker Change: Yes.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: [music].
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: [music].
Speaker Change: Yes.
Speaker Change: [music].
Speaker Change: Yes.
Speaker Change: Sure.
Speaker Change: [music].
Okay.
Speaker Change: Yes.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Sure.